KALA vs KAPA

KALA BIO, Inc. vs Kairos Pharma, Ltd. — Valuation Comparison 2026

KALA

Biotechnology
KALA BIO, Inc.
Quality
3.4
out of 10
Value Trap
24
SAFE
Price
$2.29
Last close
Models
7/13
Active
VS

KAPA

Biotechnology
Kairos Pharma, Ltd.
Quality
4.6
out of 10
Value Trap
12
SAFE
Price
$0.53
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType KALA Fair ValueKALA Upside KAPA Fair ValueKAPA Upside
Bayesian DCF Intrinsic $0.06 -97.5% $0.20 -62.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.36 -84.1% $0.02 -96.2%
Dynamic NAV Asset-Based $4.24 +85.0% $0.23 -57.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KALA vs KAPA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KALA vs KAPA — Which Stock Is More Undervalued?

KAPA scores higher with a 4.6/10 quality rating vs KALA's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing KALA BIO, Inc. (KALA) and Kairos Pharma, Ltd. (KAPA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KALA currently trades at $2.29 with a QOC of 3.4/10, while KAPA trades at $0.53 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).